The U.S. Food and Drug Administration approved Omisirge, a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a...
Merck, known as MSD outside of the United States and Canada, announced results from the Phase 3 KEYNOTE-966 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy,...
EVERSANA, a leading provider of commercialization services to the life science industry, announced a partnership with ChemoMouthpiece, LLC to support the launch and commercialization...
Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy...
